ArticleCommunications biology2025
Integrating multi-omics to reveal the molecular mechanism of lipid metabolism regulated by a splice variant of Lysyl-oxidase like-2, LOXL2Δ13.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
LOXL2Δ13, a splice variant of Lysyl-oxidase like-2 (LOXL2), enhances glucose metabolism and induces adipose depletion in mice. The precise role of LOXL2Δ13 in lipid metabolism is unclear. Through multi-omics integration, we analyzed the transcriptome, metabolome, proteome, and protein modifications profiles in LOXL2Δ13 overexpression mice. Molecular dynamics simulation and interaction mass spectrometry confirmed key biomarkers influenced by LOXL2Δ13. Here, LOXL2Δ13 was found to cause diglyceride and glycerophospholipid accumulation and alter kinase activities in pathways. Differentially expressed genes, proteins, and metabolites were enriched in lipid metabolism pathways, indicating LOXL2Δ13 influences metabolic enzyme activity by regulating protein expression and modifications. Further immunoprecipitation assay demonstrated that four proteins (Itpr1, Acat1, Canx, and Pdia3) directly interact with LOXL2∆13. This suggests that LOXL2∆13 can regulate lipid metabolic pathways through direct interactions affecting the activity of these key proteins, which in turn induce alterations in their phosphorylation or acetylation modifications, thereby affecting the lipid metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.